Aldosterone antagonist decreases blood pressure and improves metabolic parameters in obese patients with the metabolic syndrome

Journal of Clinical Hypertension

Volumn 12, Issue 9, 2010, Pages 753-755

  Costa, Monica Barros ^a   Andrade Ezequiel, Danielle Guedes ^a   Morais Lovis, Julio Cesar ^a   Oliveira, Manoel Marques ^a   Baumgratz de Paula, Rogerio ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POTASSIUM; RENIN; SPIRONOLACTONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTERY DIAMETER; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LETTER; LIPID METABOLISM; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MICROALBUMINURIA; OBESITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; AGED; ALDOSTERONE ANTAGONISTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 77956244291     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00339.x     Document Type: Letter

References (12)

1. Garrison RJ, Kannel WB, Stokes J. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:235-251.
2. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
3. He J, Whelton PK, Appel JL. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000, 35:544-549.
4. Strazzullo P, Galletti F, Barba G. Altered renal handling of sodium in human hypertension. Hypertension 2003, 41:1000-1005.
5. Granger JP, West D, Scott J. Abnormal pressure natriuresis in the dog model of obesity-induced hypertension. Hypertension 1994, 23(1 supp):I8-I11.
6. Sharma AM, Janke J, Gorzelniak K. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002, 40:609-611.
7. Reisen E, Weir M, Falkner B. Lisinopril versus hydrochlorothiazide in obese hypertensive patients. Hypertension 1997, 30:140-145.
8. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:1-7.
9. Rocha R, Stier CT, Kifor I. A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
10. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
11. Calhoun DA, Jones D, Textor S. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
12. Celermajer DS, Sorensen KE, Gooch VM. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.